"Bio-engineered stent market to exhibit dynamic growth during the forecast period"
The global bio-engineered stent market is growing proficiently, expected to grow at a CAGR of 7.1%. Globally, growing prevalence of coronary heart diseases and other hearing related disorders will drive the market growth. Growing awareness about new medical technology along with the launch of advanced bio-engineered cardiac stents or coronary stents with integrated biological solutions and enhanced biomaterials are factors driving the overall growth of bio-engineered stent market on a global scale.
"Medical grade stainless steel segment expected to register higher growth by the end of 2028"
Advancement in biodegradable metals for cardiovascular stents along with the development in the field of alloys will enhance the overall growth of the market. Metallic stents are usually used to endorse revascularization and preserve the patency of damaged arteries following angioplasty procedures. The intrinsic surface and mechanical properties of metals make them more attractive. For e.g. Genous Bio-engineered stent, it has an exceptional dual helix design that delivers natural conformability and has endothelial progenitor cell capture technology to defend counter to thrombus (blood clotting) and minimizes the recurrence of abnormal narrowing of an artery or valve by accelerating the natural restorative process.
"Coronary heart diseases to witness a significant CAGR"
Increasing hospital admissions for coronary heart-related disorders and its treatment generated maximum revenue share in 2018. Additionally, large patient pool with cardiovascular diseases and individuals for the early diagnosis of heart related conditions on a global scale will drive the market growth globally. In 2017, according to statistics by American College of Cardiology, cardiovascular disease accounted for more than 800,000 deaths in the United States. Additionally, increasing prevalence for acute coronary syndrome, ischemic heart disease, and peripheral artery disease will drive the demand for bio-engineered stent market. Advancement in bioengineering technology, FDA approval of new products, increasing geriatric population, and awareness, offers potential advantage as an elective treatment to high cost cardiac surgical procedures, and wide usage of top applications in the stent industry.
"Increasing geriatric population, FDA approval and the presence of top manufacturers holds North America in dominant position"
In 2018, the U.S. produced maximum revenue in the bio-engineered stent market due to an increase in prevalence for cardiovascular disorders, increasing hospitals admissions for coronary heart disease treatment and launch of new products will boost the market growth. Presently, more than 92 million U.S. citizens are living with some form of cardiovascular condition or the after-effects of stroke. According to a 2016 study by American Heart Association, overall direct medical expenditure of cardiovascular diseases are projected to surge to around $749 billion in 2035 globally. Existence of numerous treatment options further upsurges patient compliance in safety and efficiency of treatment for cardiovascular-related disorders which in turn expected to drive the market growth. However, the higher expense of surgical procedures, less popularity among the physicians in the developed regions, complexity in R&D, and controlled returns may hamper the overall market growth on a global scale.
"Increased research and development with strong product pipelines in the developed regions"
Major players in the bio-engineered stent market are ORBUSNEICH MEDICAL, Medtronic, plc., Abbott Laboratories, Vascular Concepts, C. R. Bard, Lombard Medical Technologies, Biotronik SE & Co. KG, Terumo Corporation, Endologix, Inc., Translumina GmbH and others. Major companies are emerging with advanced technologies with integrated biological solutions. Acquisitions, partnership agreements and enhanced R&D on medical technology will invent the development of bio-engineered stent market in the emerging nations in the near future.
Historical & Forecast Period
This study report represents analysis of each segment from 2024 to 2034 considering 2025 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2026 to 2034.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Bio-engineered Stent market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2024-2034 |
| Base Year | 2025 |
| Forecast Period | 2026-2034 |
| Historical Year | 2024 |
| Unit | USD Million |
| Segmentation | |
Material
|
|
Disease Indication
|
|
End-user
|
|
|
Region Segment (2024-2034; US$ Million)
|
Key questions answered in this report
